<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5161">
  <stage>Registered</stage>
  <submitdate>21/12/2009</submitdate>
  <approvaldate>21/12/2009</approvaldate>
  <nctid>NCT01038583</nctid>
  <trial_identification>
    <studytitle>Aspirin in Reducing Events in the Elderly</studytitle>
    <scientifictitle>Aspirin in Reducing Events in the Elderly</scientifictitle>
    <utrn />
    <trialacronym>ASPREE</trialacronym>
    <secondaryid>3U01AG029824-02S1</secondaryid>
    <secondaryid>HSR#09-3029</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Functional Disability</healthcondition>
    <healthcondition>Dementia</healthcondition>
    <healthcondition>Heart Disease</healthcondition>
    <healthcondition>Stroke</healthcondition>
    <healthcondition>Cancer</healthcondition>
    <healthcondition>Bleeding</healthcondition>
    <healthcondition>Depression</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - 100 mg enteric-coated aspirin
Treatment: drugs - Placebo

Active Comparator: Aspirin - 100 mg enteric-coated aspirin

Placebo Comparator: Placebo - Placebo


Treatment: drugs: 100 mg enteric-coated aspirin
100 mg enteric-coated aspirin, taken daily

Treatment: drugs: Placebo
100 mg enteric-coated placebo

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint is death from any cause or incident, dementia or persistent physical disability.</outcome>
      <timepoint>every 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>All-cause mortality</outcome>
      <timepoint>every 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fatal and non fatal cardiovascular events including a) coronary heart disease death, b) non-fatal MI, c) fatal and non-fatal stroke and d) any hospitalization for heart failure</outcome>
      <timepoint>every 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fatal and non-fatal cancer, excluding non-melanoma skin cancer</outcome>
      <timepoint>every 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dementia</outcome>
      <timepoint>every 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mild Cognitive Impairment (MCI; assessed using the Modified Mini-Mental State Examination or 3MS 70 and other cognitive function measures - see below)</outcome>
      <timepoint>every 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physical disability</outcome>
      <timepoint>every 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Major hemorrhagic events</outcome>
      <timepoint>every 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Depression</outcome>
      <timepoint>Annually</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Men and women

          -  African American and Hispanic persons age 65 or older

          -  Any person from another ethnic minority group and Caucasian persons age 70 or older

          -  Willing and able to provide informed consent, and willing to accept the study
             requirements</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  A history of a diagnosed cardiovascular event

          -  A serious intercurrent illness likely to cause death within the next 5 years, such as
             terminal cancer or obstructive airways disease

          -  A current or recurrent condition with a high risk of major bleeding, ex: cerebral
             aneurysm

          -  Anemia

          -  Absolute contraindication or allergy to aspirin

          -  Current participation in a clinical trial

          -  Current continuous use of aspirin or other anti-platelet drug or anticoagulant for
             secondary prevention. People with previous use of aspirin for primary prevention may
             enter the trial, provided they agree to cease existing use of aspirin and understand
             that they may be subsequently randomly allocated to low dose aspirin or placebo.

          -  A systolic blood pressure =180 mmHg and / or a diastolic blood pressure =105 mmHg

          -  A history of dementia

          -  Severe difficulty or an inability to perform any one of the 6 Katz ADLs

          -  Non-compliance to taking pill</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>19000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,SA,TAS,VIC</recruitmentstate>
    <hospital>Clinical Trials Unit, The Canberra Hospital - Garran</hospital>
    <hospital>Illawarra Health and Medical Research Institute, University of Wollongong - Wollongong</hospital>
    <hospital>Discipline of General Practice, School of Population Health, University of Adelaide - Adelaide, SA 5005</hospital>
    <hospital>Greater Green Triangle University - Mount Gambier</hospital>
    <hospital>University of Tasmania Rural Clinical School - Burnie</hospital>
    <hospital>The Menzies Institute for Medical Research, University of Tasmania - Hobart</hospital>
    <hospital>University of Tasmania Newnham Campus - Launceston</hospital>
    <hospital>Bendigo Regional Clinical School - Bendigo</hospital>
    <hospital>Geelong Hospital - Geelong</hospital>
    <hospital>Monash Mildura Regional Clinical School - Mildura West</hospital>
    <hospital>University of Ballarat - Mount Helen</hospital>
    <hospital>Monash Gippsland Regional Clinical School - Traralgon</hospital>
    <hospital>The South West Alliance of Rural Health (SWARH) - Warrnambool</hospital>
    <hospital>Gateway Community Health - Wodonga</hospital>
    <postcode>2605 - Garran</postcode>
    <postcode>2522 - Wollongong</postcode>
    <postcode>5005 - Adelaide, SA 5005</postcode>
    <postcode>5290 - Mount Gambier</postcode>
    <postcode>7320 - Burnie</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>7250 - Launceston</postcode>
    <postcode>3550 - Bendigo</postcode>
    <postcode>3220 - Geelong</postcode>
    <postcode>3500 - Mildura West</postcode>
    <postcode>3350 - Mount Helen</postcode>
    <postcode>3844 - Traralgon</postcode>
    <postcode>3280 - Warrnambool</postcode>
    <postcode>3690 - Wodonga</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Minneapolis Medical Research Foundation</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Bayer</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Monash University</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Berman Center for Outcomes and Clinical Research</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Institute on Aging (NIA)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The ASPREE study will examine whether the potential benefits of low dose aspirin
      (particularly preventing heart disease, stroke, certain cancers and dementia) outweigh the
      risks (particularly bleeding) in people over age 65.

      ASPREE will determine whether taking a daily low-dose aspirin will extend the length of a
      disability-free life in healthy participants aged 65 years and above.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01038583</trialwebsite>
    <publication>Barker AL, McNeil JJ, Seeman E, Ward SA, Sanders KM, Khosla S, Cumming RG, Pasco JA, Bohensky MA, Ebeling PR, Woods RL, Lockery JE, Wolfe R, Talevski J; ASPREE Investigator Group. A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: protocol for the ASPREE-Fracture substudy. Inj Prev. 2016 Aug;22(4):297-301. doi: 10.1136/injuryprev-2015-041655. Epub 2015 May 21.
ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013 Nov;36(2):555-64. doi: 10.1016/j.cct.2013.09.014. Epub 2013 Oct 7.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Anne Murray, MD, MSc</name>
      <address>Berman Center for Outcomes and Clinical Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>